South Dakota Senate Bill SB194

South Dakota 2026 Regular Session

• Introduced: 1/29/26
• Refer: 1/29/26

Caption

Limit the potency of cannabis products sold at medical cannabis dispensaries.

Impact

If enacted, SB194 would significantly impact the medical cannabis industry in South Dakota by enforcing stricter regulations on product potency. Advocates of the bill argue that these limits will help protect patients from potential adverse effects associated with very high THC levels. They contend that regulating the concentration of THC is essential for ensuring safe consumption practices among medical cannabis users, particularly those who may be new to using such products or those with heightened sensitivity to psychoactive effects. However, this bill may also affect the variety and availability of products, potentially limiting choices for patients who rely on different forms of cannabis for their conditions.

Summary

Senate Bill 194 aims to regulate the potency of cannabis products sold at medical cannabis dispensaries in South Dakota. The bill introduces explicit limits on the tetrahydrocannabinol (THC) levels for various cannabis products. Specifically, it prohibits the sale of cannabis flower containing more than thirty percent THC, liquid concentrates exceeding sixty percent THC, and edibles with more than five milligrams of THC per serving or one hundred milligrams per container. Additionally, cannabis oil is restricted to a maximum of five percent THC. This legislation reflects a growing concern regarding the strength of cannabis products available to patients using medical cannabis.

Contention

The discussion around SB194 indicates a divide among stakeholders. Supporters, including some lawmakers and health advocates, underscore the need for consumer safety and the regulation of strong cannabis products. Opponents, potentially including dispensary owners and some cannabis advocates, may express concerns regarding the bill's potential to restrict patients' access to effective treatment options. The limits on product potency could be viewed as an overreach of legislative authority into a market that has already shown significant growth and acceptance, raising questions about patient autonomy and the ability of dispensaries to cater to diverse patient needs.